drugset / Trial / NCT06411457
SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer
Timeline
- Start
- 2024-05-16
- Primary completion
- 2025-05-01
- Completion
- 2026-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | 6.4 mg/kg | Intravenous |